Ebos Group (NZSE:EBO) Debt-to-Revenue : 0.14 (As of Dec. 2023)

View and export this data going back to 1960. Start your Free Trial

What is Ebos Group Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Ebos Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NZ$245 Mil. Ebos Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NZ$1,731 Mil. Ebos Group's annualized Revenue for the quarter that ended in Dec. 2023 was NZ$14,176 Mil. Ebos Group's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.14.

Ebos Group Debt-to-Revenue Historical Data

The historical data trend for Ebos Group's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ebos Group Debt-to-Revenue Chart

Ebos Group Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Revenue

Get a 7-Day Free Trial

0.08

0.09

0.07

0.15

0.11

Ebos Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															0.05	0.15	0.11	0.10	0.14

Competitive Comparison of Ebos Group's Debt-to-Revenue

For the Medical Distribution subindustry, Ebos Group's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ebos Group's Debt-to-Revenue Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Ebos Group's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Ebos Group's Debt-to-Revenue falls into.

Ebos Group Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Ebos Group's Debt-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(100.409	+	1295.763)	/	13317.446
	=	0.10

Ebos Group's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(245.03	+	1731.151)	/	14175.704
	=	0.14

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.

Ebos Group Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ebos Group's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Ebos Group (NZSE:EBO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Ebos Group Ltd (NZSE:EBO) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

EJG:Germany EBO:Australia

Address

108 Wrights Road, P.O. Box 411, Christchurch, STL, NZL, 8024

Website

https://www.ebosgroup.com

Ebos is the largest pharmaceutical wholesaler and distributor across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 60% and 30% of revenue respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low single digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.

Ebos Group (NZSE:EBO) Headlines

No Headlines